三阴性乳腺癌辅助化疗预后生物标志物的研究进展

郭凤珠; 李芷君; 徐兵河

doi:10.12354/j.issn.1000-8179.2021.20211156

三阴性乳腺癌辅助化疗预后生物标志物的研究进展

doi: 10.12354/j.issn.1000-8179.2021.20211156

郭凤珠^{1, 2,},
李芷君¹,
徐兵河^1, ,

1.
国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院肿瘤内科（北京市100021）
2.
分子肿瘤学国家重点实验室

详细信息

作者简介:
郭凤珠：专业方向为乳腺癌的基础与临床研究

通讯作者:
徐兵河　xubinghe@medmail.com.cn

计量
- 文章访问数: 265
- HTML全文浏览量: 38
- PDF下载量: 83
- 被引次数: 0
出版历程
- 收稿日期: 2021-07-29
- 网络出版日期: 2022-01-12

Progress in prognostic biomarkers for triple-negative breast cancer in patients undergoing adjuvant chemotherapy

Fengzhu Guo^{1, 2
,},
Zhijun Li¹,
Binghe Xu^{1
, ,}

1.
Department of Medical Oncology
2.
State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College，Beijing 100021, China

More Information

Corresponding author: Binghe Xu; E-mail: xubinghe@medmail.com.cn

摘要

摘要: 三阴性乳腺癌（triple-negative breast cancer，TNBC）具有组织学分级高、临床分期晚、侵袭性强、易发生转移等特点。由于缺乏有效的治疗靶点，传统化疗仍是TNBC患者主要的治疗选择。作为高度异质性疾病，TNBC需要更为精确的预测生物标志物。组学技术的发展及临床试验的实施为辅助化疗预后生物标志物带来新的探索，涵盖基因、蛋白及微环境成分等不同维度，也包括多分子的联合分析应用。本文将对TNBC辅助化疗预后生物标志物及其潜在分子机制与未来发展方向进行综述。
- 三阴性乳腺癌 /
- 预后 /
- 生物标志物 /
- 辅助化疗
Abstract: Triple-negative breast cancer (TNBC) is characterized by high histological grade, advanced clinical stage, invasiveness, and high incidence of metastasis. Because of the lack of effective therapeutic targets, traditional chemotherapy remains the mainstay for treating patients with TNBC. As a highly heterogeneous disease, TNBC requires more accurate predictive biomarkers. The development of omics techniques and initiation of clinical trials have become avenues for exploration of new prognostic biomarkers of adjuvant chemotherapy, encompassing different elements such as genes, proteins, and components of the microenvironment, as well as the multi-molecule combined analysis. Thus, in this review, we summarize prognostic biomarkers for TNBC in patients undergoing adjuvant chemotherapy, potential molecular mechanisms, and directions for future development.
- triple-negative breast cancer (TNBC) /
- prognosis /
- biomarker /
- adjuvant chemotherapy

HTML全文

参考文献(25)

[1]	Cocco S, Piezzo M, Calabrese A, et al. Biomarkers in triple-negative breast cancer: state-of-the-art and future perspectives[J]. Int J Mol Sci, 2020, 21(13):4579. doi: 10.3390/ijms21134579
[2]	Sharma P, Barlow WE, Godwin AK, et al. Impact of homologous recombination deficiency biomarkers on outcomes in patients with triple-negative breast cancer treated with adjuvant doxorubicin and cyclophosphamide (SWOG S9313)[J]. Ann Oncol, 2018, 29(3):654-660.
[3]	中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2019年版)[J].中国癌症杂志,2019,29(8):609-680.
[4]	Li J, Yu K, Pang D, et al. Adjuvant capecitabine with docetaxel and cyclophosphamide plus epirubicin for triple-negative breast cancer (CBCSG010): an open-label, randomized, multicenter, phase III trial[J]. J Clin Oncol, 2020, 38(16):1774-1784. doi: 10.1200/JCO.19.02474
[5]	Yuan Z, Hua X, Li W-Z, et al. Predict the benefit of metronomic capecitabine maintenance in early-stage triple-negative breast cancer: Results from the SYSUCC-001 study[J]. J Clin Oncol, 2021, 39(15_Suppl):521-521. doi: 10.1200/JCO.2021.39.15_suppl.521
[6]	Yu KD, Ye FG, He M, et al. Effect of adjuvant paclitaxel and carboplatin on survival in women with triple-negative breast cancer: aphase 3 randomized clinical trial[J]. JAMA Oncol, 2020, 6(9):1390-1396. doi: 10.1001/jamaoncol.2020.2965
[7]	Telli ML, Timms KM, Reid J, et al. Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer[J]. Clin Cancer Res, 2016, 22(15):3764-3773. doi: 10.1158/1078-0432.CCR-15-2477
[8]	Boissière-Michot F, Chabab G, Mollevi C, et al. Clinicopathological correlates of γδ T cell infiltration in triple-negative breast cancer[J]. Cancers (Basel), 2021, 13(4):765.
[9]	Ignatov T, Poehlmann A, Ignatov A, et al. BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC[J]. Breast Cancer Res Treat, 2013, 141(2):205-212.
[10]	Jacot W, Lopez-Crapez E, Mollevi C, et al. BRCA1 promoter hypermethylation is associated with good prognosis and chemosensitivity in triple-negative breast cancer[J]. Cancers (Basel), 2020, 12(4):828.
[11]	Bosnjak M, Jesenko T, Markelc B, et al. PARP inhibitor olaparib has a potential to increase the effectiveness of electrochemotherapy in BRCA1 mutated breast cancer in mice[J]. Bioelectrochemistry, 2021, 140:107832. doi: 10.1016/j.bioelechem.2021.107832
[12]	Liao Y, Liao Y, Li J, et al. Polymorphisms in PARP1 predict disease-free survival of triple-negative breast cancer patients treated with anthracycline/taxane based adjuvant chemotherapy[J]. Sci Rep, 2020, 10(1):7349. doi: 10.1038/s41598-020-64473-8
[13]	Wei LY, Zhang XJ, Wang L, et al. A six-epithelial-mesenchymal transition gene signature may predict metastasis of triple-negative breast cancer[J]. Onco Targets Ther, 2020, 13:6497-6509. doi: 10.2147/OTT.S256818
[14]	Abdel-Fatah TM, Perry C, Dickinson P, et al. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings[J]. Ann Oncol, 2013, 24(11):2801-2807. doi: 10.1093/annonc/mdt277
[15]	Tawfik K, Kimler BF, Davis MK, et al. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors[J]. Hum Pathol, 2012, 43(1):23-30. doi: 10.1016/j.humpath.2011.04.011
[16]	Xu YL, Yao R, Li J, et al. FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer[J]. Cancer Chemother Pharmacol, 2017, 79(6):1205-1213.
[17]	PedersenMH, Hood BL, Beck HC, et al. Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumors[J]. OncoImmunology, 2017, 6(5):e1305531.
[18]	Pedersen MH, Hood BL, Ehmsen S, et al. CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients[J]. Int J Cancer, 2019, 144(3):631-640.
[19]	Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies[J]. J Clin Invest, 2011, 121(7):2750-2767. doi: 10.1172/JCI45014
[20]	Wilson TR, Yu J, Lu X, et al. The molecular landscape of high-risk early breast cancer: comprehensive biomarker analysis of a phase Ⅲ adjuvant population[J]. NPJ Breast Cancer, 2016, 2:16022. doi: 10.1038/npjbcancer.2016.22
[21]	Asleh K, Brauer HA, Sullivan A, et al. Predictive biomarkers for adjuvant capecitabine benefit in early-stage triple-negative breast cancer in the FinXX clinical trial[J]. Clin Cancer Res, 2020, 26(11):2603-2614.
[22]	Schmid P, Rugo HS, Adams S, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2020, 21(1):44-59. doi: 10.1016/S1470-2045(19)30689-8
[23]	Diana A, Carlino F, Franzese E, et al. Early triple negative breast cancer: conventional treatment and emerging therapeutic landscapes[J]. Cancers (Basel), 2020, 12(4):819.
[24]	Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase Ⅲ randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98[J]. J Clin Oncol, 2013, 31(7):860-867. doi: 10.1200/JCO.2011.41.0902
[25]	Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase Ⅲ randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199[J]. J Clin Oncol, 2014, 32(27):2959-2966.